Harvard Bioscience FY 2025 goodwill impairment hits USD 47.95 million as revenue falls 8% to USD 86.55 million

Reuters03-13

Harvard Bioscience FY 2025 goodwill impairment hits USD 47.95 million as revenue falls 8% to USD 86.55 million

Revenue fell 8% to USD 86.55 million as demand softened from distributors, CROs and academic medical research institutions.
Gross profit declined 9% to USD 49.91 million, with gross margin at 57.7% versus 58.2% a year earlier due to under-absorption of fixed manufacturing overhead partly offset by product mix and lower labor costs.
A USD 47.95 million goodwill impairment was recorded after a quantitative impairment analysis found carrying value exceeded fair value by USD 48 million.
Interest expense rose 39% to USD 4.92 million, primarily due to a higher interest rate margin under amendments to the prior credit facilities.
Operating cash flow was USD 6.73 million, and cash and cash equivalents were USD 8.6 million with borrowings outstanding of USD 40 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001548), on March 13, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619192653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619192653","market":"nz","top_or_hot":-1,"title":"Harvard Bioscience FY 2025 goodwill impairment hits USD 47.95 million as revenue falls 8% to USD 86.55 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harvard Bioscience FY 2025 goodwill impairment hits USD 47.95 million as revenue falls 8% to USD 86.55 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Revenue fell 8% to USD 86.55 million as demand softened from distributors, CROs and academic medical research institutions.\n        </li>\n<li>\n          Gross profit declined 9% to USD 49.91 million, with gross margin at 57.7% versus 58.2% a year earlier due to under-absorption of fixed manufacturing overhead partly offset by product mix and lower labor costs.\n        </li>\n<li>\n          A USD 47.95 million goodwill impairment was recorded after a quantitative impairment analysis found carrying value exceeded fair value by USD 48 million.\n        </li>\n<li>\n          Interest expense rose 39% to USD 4.92 million, primarily due to a higher interest rate margin under amendments to the prior credit facilities.\n        </li>\n<li>\n          Operating cash flow was USD 6.73 million, and cash and cash equivalents were USD 8.6 million with borrowings outstanding of USD 40 million.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001548), on March 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Harvard Bioscience FY 2025 goodwill impairment hits USD 47.95 million as revenue falls 8% to USD 86.55 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHarvard Bioscience FY 2025 goodwill impairment hits USD 47.95 million as revenue falls 8% to USD 86.55 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-13 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Harvard Bioscience FY 2025 goodwill impairment hits USD 47.95 million as revenue falls 8% to USD 86.55 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Revenue fell 8% to USD 86.55 million as demand softened from distributors, CROs and academic medical research institutions.\n        </li>\n<li>\n          Gross profit declined 9% to USD 49.91 million, with gross margin at 57.7% versus 58.2% a year earlier due to under-absorption of fixed manufacturing overhead partly offset by product mix and lower labor costs.\n        </li>\n<li>\n          A USD 47.95 million goodwill impairment was recorded after a quantitative impairment analysis found carrying value exceeded fair value by USD 48 million.\n        </li>\n<li>\n          Interest expense rose 39% to USD 4.92 million, primarily due to a higher interest rate margin under amendments to the prior credit facilities.\n        </li>\n<li>\n          Operating cash flow was USD 6.73 million, and cash and cash equivalents were USD 8.6 million with borrowings outstanding of USD 40 million.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001548), on March 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HBIO","symbol_name":"哈佛生物科学","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDLVT6kt:1","article_id":"2619192653","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619192653","pubTimestamp":1773404583,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Revenue fell 8% to USD 86.55 million as demand softened from distributors, CROs and academic medical research institutions.Gross profit declined 9% to USD 49.91 million, with gross margin at 57.7% versus 58.2% a year earlier due to under-absorption of fixed manufacturing overhead partly offset by product mix and lower labor costs.A USD 47.95 million goodwill impairment was recorded after a quantitative impairment analysis found carrying value exceeded fair value by USD 48 million.Interest expense rose 39% to USD 4.92 million, primarily due to a higher interest rate margin under amendments to the prior credit facilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HBIO":"哈佛生物科学","BK4121":"生命科学工具和服务"},"translate_title":"哈佛生物科学2025财年商誉减值达到4795万美元，收入下降8%至8655万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HBIO":0.9},"content_text":"Harvard Bioscience FY 2025 goodwill impairment hits USD 47.95 million as revenue falls 8% to USD 86.55 million\n    \n\n\n          Revenue fell 8% to USD 86.55 million as demand softened from distributors, CROs and academic medical research institutions.\n        \n\n          Gross profit declined 9% to USD 49.91 million, with gross margin at 57.7% versus 58.2% a year earlier due to under-absorption of fixed manufacturing overhead partly offset by product mix and lower labor costs.\n        \n\n          A USD 47.95 million goodwill impairment was recorded after a quantitative impairment analysis found carrying value exceeded fair value by USD 48 million.\n        \n\n          Interest expense rose 39% to USD 4.92 million, primarily due to a higher interest rate margin under amendments to the prior credit facilities.\n        \n\n          Operating cash flow was USD 6.73 million, and cash and cash equivalents were USD 8.6 million with borrowings outstanding of USD 40 million.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001548), on March 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619192653","isCrawlerRequest":true}